PD-L1 status has previously been described as a predictive biomarker of response to PD-1 inhibitor monotherapy in numerous malignancies, such as non-small cell lung cancer and head and neck squamous cell carcinoma [30,31,32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.